Can Gene Therapy be the Solution for Congestive Heart Failure?-AskBio

Video Transcription

Video Summary

The webinar entitled "Can Gene Therapy be the Solution for Congestive Heart Failure?" was sponsored by ASBAU, a gene therapy company affiliated with Bayer. The webinar was led by Alain Lamontagne, the Head of Global Medical Affairs at ASBAU. The objectives of the webinar were to provide an overview of congestive gene therapy in CHF, discuss the mechanism of action of ANN101, review the initial data from a phase one clinical trial, and preview the design of the upcoming phase two gene fit clinical study. The speakers in the webinar included Dr. Raja Hajjar from Flagship Paranay, who provided an overview of cardiac gene therapy in CHF, Dr. Liza Kranius from the University of Cincinnati, who discussed the mechanism of action of ANN101, and Dr. Tim Henry from the Chris Hospital Health Network, who shared the initial data from the phase one clinical trial. The webinar highlighted the potential of gene therapy as a treatment for congestive heart failure and provided insights into the development and efficacy of ANN101. The presentation concluded with the announcement of a phase two trial, GeneFit, which will further evaluate the safety and efficacy of ANN101 in patients with non-ischemic cardiomyopathy and New York Heart Association Class III heart failure.

Keywords

webinar

gene therapy

congestive heart failure

ASBAU

ANN101

clinical trial

efficacy

GeneFit